A supplemental new drug application from Melinta Therapeutics for the use of Baxdela, or delafloxacin, in adult patients with community-acquired bacterial pneumonia, has been accepted by the FDA under priority review status. The agency set the PDUFA date of Oct. 24.
FDA accepts Melinta's Baxdela under priority status
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.